ORAGENICS INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | $37,653 | $131,521 | $86,987 |
| Research and development | $2.4M | $4.1M | $15.5M | $10.1M | $10.6M |
| Operating expenses | $9.4M | $10.6M | $20.9M | $14.6M | $15.9M |
| Operating income | -$9.4M | -$10.6M | -$20.9M | -$14.4M | -$15.8M |
| Interest expense | $785,930 | $29,828 | $30,591 | $15,103 | $15,756 |
| Pretax income | -$10.0M | -$10.6M | -$20.7M | -$14.3M | -$15.7M |
| Income tax expense | -$136,910 | — | — | — | — |
| Net income | -$9.8M | -$10.6M | -$20.7M | -$14.3M | -$15.7M |
| Balance Sheet | |||||
| Cash and equivalents | $4.4M | $864,840 | $3.5M | $11.4M | $27.3M |
| Current assets | $10.1M | $1.5M | $3.9M | $14.3M | $27.7M |
| Total assets | $10.1M | $1.5M | $5.0M | $14.8M | $28.2M |
| Current liabilities | — | — | $1.8M | $1.6M | $1.4M |
| Total liabilities | $1.8M | $1.7M | $1.8M | — | — |
| Stockholders' equity | $8.3M | -$211,885 | $3.2M | $13.0M | $26.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$9.2M | -$8.6M | -$7.3M | -$15.2M | -$13.5M |
| Depreciation and amortization | — | — | $27,391 | $44,667 | $41,237 |
| Stock-based compensation | $642,364 | $516,049 | $1.0M | $742,203 | $1.7M |
| Capital expenditure | — | — | — | $127,519 | $43,876 |
| Free cash flow | — | — | — | -$15.4M | -$13.5M |
Shares outstanding 4.5M · Free float 82.0%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.